Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innova...
Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatme...
TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymph...
Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innova...
